HB Wealth Management LLC Sells 1,254 Shares of Pfizer Inc. (NYSE:PFE)

HB Wealth Management LLC lessened its position in Pfizer Inc. (NYSE:PFE) by 0.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 198,360 shares of the biopharmaceutical company’s stock after selling 1,254 shares during the quarter. HB Wealth Management LLC’s holdings in Pfizer were worth $5,263,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PFE. Retirement Wealth Solutions LLC bought a new stake in Pfizer during the 4th quarter valued at approximately $26,000. Gladius Capital Management LP boosted its position in shares of Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 38,015 shares during the period. Quarry LP acquired a new stake in shares of Pfizer in the second quarter worth $31,000. Teachers Insurance & Annuity Association of America bought a new position in Pfizer during the third quarter worth $35,000. Finally, Joseph Group Capital Management raised its stake in Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 771 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

NYSE:PFE opened at $26.30 on Friday. The firm has a market cap of $149.06 billion, a PE ratio of 35.55, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company’s 50-day moving average price is $26.08 and its two-hundred day moving average price is $27.99. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 12 month low of $24.48 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the prior year, the company earned ($0.17) EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a yield of 6.54%. Pfizer’s dividend payout ratio is 232.43%.

Insiders Place Their Bets

In related news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on PFE. Wolfe Research began coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective on the stock. Sanford C. Bernstein started coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Citigroup started coverage on Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. Finally, Truist Financial decreased their price target on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.